Effect of Combination Therapy with Ezetimibe and Statins versus Statin Monotherapy on Carotid Intima-Media Thickness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q3Scopus Q2
- 저널
- MEDICINA-LITHUANIA59(11) · 2023
- 피인용
- Web of Science 4Scopus 5
- FWCI (Scopus)
- 0.64
- JCR IF
- JCR 2022 2.6
- ISSN
- 1010-660X
저자
- 권력준제1저자Pusan Natl Univ, Yangsan Hosp, Family Med Clin, Yangsan 50612, South Korea
- 조영혜Pusan Natl Univ, Sch Med, Dept Family Med, Yangsan 50612, South Korea
- 박은주Pusan Natl Univ, Yangsan Hosp, Family Med Clin, Yangsan 50612, South Korea
- 이영인Pusan Natl Univ, Yangsan Hosp, Family Med Clin, Yangsan 50612, South Korea
- 이새롬Pusan Natl Univ, Yangsan Hosp, Family Med Clin, Yangsan 50612, South Korea
- 최정인Pusan Natl Univ, Yangsan Hosp, Family Med Clin, Yangsan 50612, South Korea
- 이상엽Pusan Natl Univ, Yangsan Hosp, Family Med Clin, Yangsan 50612, South Korea
- 손수민교신저자Pusan Natl Univ, Yangsan Hosp, Family Med Clin, Yangsan 50612, South Korea
초록
Background and Objectives: Lipid-lowering agents such as ezetimibe are recommended in uncontrolled hyperlipidemia for primary and secondary prevention of cardiovascular disease. Carotid intima-media thickness (CIMT) is a surrogate marker of atherosclerosis and a predictor of cardiovascular and cerebral events. The effects of ezetimibe on CIMT have been inconsistently reported. The aim of this meta-analysis is to compare the effects of ezetimibe/statin and statin alone therapies on CIMT reduction. Materials and Methods: The PubMed, Embase, and Cochrane library databases were searched for randomized controlled trials (RCTs) published prior to 26 January 2023 with the MeSH keywords 'Ezetimibe' and 'Carotid Intima-Media Thickness'. The results were presented as standard mean difference (SMD) with 95% confidence intervals using the random-effect model method, and heterogeneity was assessed. Subgroup, meta-regression, and sensitivity analyses were conducted. Results: Five RCTs with 642 participants were included. CIMT reduction was not significantly different between the ezetimibe/statin and statin alone groups. However, in subgroup analyses, CIMT in the ezetimibe/statin group was significantly reduced in patients with non-familial hypercholesterolemia (SMD: -0.34 mm and p = 0.002) and in patients with secondary prevention (SMD: -0.38 mm and p = 0.002). The low-density lipoprotein cholesterol level was significantly reduced in the ezetimibe/statin group (SMD: -0.58 mg/dL and p < 0.001). Conclusions: The effect of ezetimibe on CIMT reduction was shown in non-familial hypercholesterolemia and secondary prevention. These results suggest that the efficacy of ezetimibe may vary with potential CIMT reduction benefits in certain subpopulations.
키워드
atherosclerosiscardiovascular diseaseezetimibeintima-media thicknessstrokeCARDIOVASCULAR RISKADDING EZETIMIBEATHEROSCLEROSISATORVASTATINSTROKEPLAQUEEFFICACYSAFETY
식별자
- Scopus EID
- 2-s2.0-85177751964
- WoS UID
- 001114539800001



로그인
연구물 목록으로